Huge bull call on BELLUS Health from Evercore implies +400% upside
Nov. 18, 2020 8:52 AM ETBELLUS Health Inc. (BLU), BLU:CABLUBy: Clark Schultz, SA News Editor1 Comment
- BELLUS Health (NASDAQ:BLU) is on watch after Evercore ISI starts off coverage with an Outperform rating.
- In a nutshell, analyst Josh Schimmer and team think the market dramatically underestimates the results of a key study.
- "The P2 study of ‘5937 missed its primary endpoint, driving shares substantially lower and resulting in a valuation that leaves BLU off most investor radar screens. We believe investors acted in accordance with the negative headline associated with the study results and NOT the underlying data/scientific rationale which is why we are so positive compared to the street."
- "But it turns out there was a surprisingly strong (and prespecified) signal within this 'failed' P2 trial – patients with more frequent cough at baseline had a clearer sign of benefit with ‘5937."
- Evercore has a price target of $12 on BLU to rep more than 400% upside potential. The Evercore PT is almost double the average Wall Street price target as well.
- BLU +7.11% premarket to $2.56.